BiotechTube

YM150 + Placebo + Enoxaparin

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism

Trial Timeline

May 1, 2009 → Mar 1, 2010

NCT ID
NCT00913120

About YM150 + Placebo + Enoxaparin

YM150 + Placebo + Enoxaparin is a phase 2/3 stage product being developed by Astellas Pharma for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00913120. Target conditions include Venous Thromboembolism.

What happened to similar drugs?

6 of 20 similar drugs in Venous Thromboembolism were approved

Approved (6) Terminated (2) Active (13)
✅Dalteparin (Fragmin) + Unfractionated heparinPfizerApproved
✅Apixaban + Standard of CarePfizerApproved
✅ApixabanBristol Myers SquibbApproved
✅enoxaparin sodiumSanofiApproved
✅enoxaparinSanofiApproved
✅Long DOAC + Short DOACBayerApproved
🔄Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00913120Phase 2/3Completed
NCT00917254Phase 2/3Completed

Competing Products

20 competing products in Venous Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
26
dalteparin injectionEisaiPhase 3
32
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
29
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K AntagonistJohnson & JohnsonPhase 2
35